Frank Leonard Sells 5,607 Shares of NovoCure (NASDAQ:NVCR) Stock

NovoCure Limited (NASDAQ:NVCR) CEO Frank Leonard sold 5,607 shares of NovoCure stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $13.31, for a total value of $74,629.17. Following the sale, the chief executive officer owned 493,793 shares of the company’s stock, valued at approximately $6,572,384.83. This represents a 1.12% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

NovoCure Price Performance

Shares of NVCR opened at $13.04 on Friday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.50 and a current ratio of 2.90. The firm has a market cap of $1.48 billion, a PE ratio of -10.69 and a beta of 0.71. NovoCure Limited has a twelve month low of $9.82 and a twelve month high of $21.55. The firm’s 50 day moving average price is $12.74 and its 200 day moving average price is $12.71.

NovoCure (NASDAQ:NVCR) last released its quarterly earnings data on Thursday, February 26th. The medical equipment provider reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.41) by $0.19. NovoCure had a negative net margin of 20.79% and a negative return on equity of 39.11%. The business had revenue of $174.35 million during the quarter, compared to analyst estimates of $174.40 million. During the same quarter in the previous year, the business earned ($0.61) EPS. NovoCure’s quarterly revenue was up 8.2% compared to the same quarter last year. As a group, research analysts expect that NovoCure Limited will post -1.3 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the stock. HC Wainwright boosted their target price on shares of NovoCure from $47.00 to $49.00 and gave the stock a “buy” rating in a research report on Thursday, February 26th. Evercore set a $20.00 target price on shares of NovoCure in a research note on Monday, January 5th. Wedbush reissued a “neutral” rating and issued a $18.00 target price on shares of NovoCure in a research note on Thursday, January 15th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of NovoCure in a report on Thursday, January 22nd. Three analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $26.93.

Institutional Investors Weigh In On NovoCure

Several institutional investors and hedge funds have recently added to or reduced their stakes in NVCR. Empowered Funds LLC acquired a new position in shares of NovoCure during the 4th quarter worth about $33,000. SJS Investment Consulting Inc. bought a new stake in NovoCure during the third quarter worth about $41,000. Kestra Advisory Services LLC bought a new stake in NovoCure during the fourth quarter worth about $49,000. Larson Financial Group LLC boosted its position in NovoCure by 662.1% during the third quarter. Larson Financial Group LLC now owns 4,100 shares of the medical equipment provider’s stock valued at $53,000 after purchasing an additional 3,562 shares during the last quarter. Finally, Headlands Technologies LLC bought a new position in NovoCure in the second quarter valued at approximately $88,000. 84.61% of the stock is owned by institutional investors.

Trending Headlines about NovoCure

Here are the key news stories impacting NovoCure this week:

• Positive Sentiment: Q4 results beat EPS expectations (reported ($0.22) vs. ($0.41) est.) and revenue rose ~8.2% year‑over‑year — a fundamental positive that supports a recovery narrative and gives analysts a basis for higher targets. MarketBeat NVCR coverage
• Positive Sentiment: Some sell‑side firms remain constructive (e.g., HC Wainwright raised its target and several analysts maintain Buy ratings), providing upside scenarios if clinical/commercial momentum continues. Analyst notes (MarketBeat)
• Neutral Sentiment: Brokerage consensus is an overall “Hold,” signaling limited near‑term conviction for a sustained re‑rating despite divergent analyst targets. NovoCure receives average “Hold” rating
• Neutral Sentiment: High institutional ownership (~84.6%) concentrates share control; that reduces free float but means large insider blocks can have outsized market impact when sold. Institutional holdings (MarketBeat)
• Neutral Sentiment: Minor individual insider sale by Michal Nath Puri (1,100 shares) is immaterial alone but contributes to the overall recent selling narrative. InsiderTrades alert
• Negative Sentiment: Chairman William F. Doyle sold a large block (71,887 shares, ≈$933k), trimming his stake by ~18% — a substantial single insider sale that markets typically read as negative signaling. SEC filing: Doyle sale
• Negative Sentiment: Multiple senior executives (COO Mukund Paravasthu, CEO Frank Leonard, CFO Christoph Brackmann and others) executed notable sales in the same window — an aggregated pattern that likely amplified selling pressure and contributed to intraday weakness. SEC filings: Executive sales summary

NovoCure Company Profile

NovoCure is a global oncology company pioneering Tumor Treating Fields (TTFields), a novel anti-mitotic therapy for solid tumors. The company’s non-invasive treatment platforms deliver low-intensity, alternating electric fields designed to disrupt cancer cell division. NovoCure’s approach offers an alternative modality to complement existing therapies in oncology, with a focus on hard-to-treat malignancies.

Founded in 2000 and headquartered in Haifa, Israel, NovoCure maintains a second operational center in Portsmouth, New Hampshire.